Clinical Trial Update: Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of linagliptin 5 mg vs placebo in adults with type 2 diabetes and severe chronic kidney impairment; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2012-02-01